Circio Holding ASA

Equities

TRVX

NO0013033795

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-06-28 am EDT			5-day change	1st Jan Change
2.45 ^NOK	-0.81%		-5.77%	-65.97%

Jun. 17	Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design	CI
Jun. 17	Transcript : Circio Holding ASA - Special Call

Circio : Flagging

June 19, 2024 at 07:19 am EDT

Flagging

18 Jun 2024 12:25 CEST

Issuer

CircioHolding ASA

Som følge av kapitalforhøyelsen i Circio Holding ASA («Selskapet») i forbindelse
med konvertering av lån til aksjer i Selskapet, registrert 6. juni 2024
(«Kapitalforhøyelsen»), har Høse AS falt under 5 %-terskelen for flagging av
vesentlige aksjeposter. Etter Kapitalforhøyelsen innehar Høse AS 500 589 aksjer
i Selskapet, tilsvarende ca. 4,7 % av Selskapets utestående aksjer og stemmer.

Denne flaggemeldingen er publisert i medhold av verdipapirhandelloven § 4-2, og
er offentliggjort i henhold til § 5-12 i verdipapirhandelloven.

More information:
Access the news on Oslo Bors NewsWeb site

Source

Circio Holding ASA

Provider

Oslo Børs Newspoint

Company Name

CIRCIO HOLDING ASA

ISIN

NO0013033795

Symbol

CRNA

Market

Oslo Børs

Attachments

Original Link
Permalink

Disclaimer

Circio Holding ASA published this content on 18 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 June 2024 11:18:21 UTC.

Latest news about Circio Holding ASA

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design	Jun. 17	CI
Transcript : Circio Holding ASA - Special Call	Jun. 16
Circio Exercises NOK4 Million Bridge Financing Deal With Atlas	Jun. 13	MT
Transcript : Circio Holding ASA - Special Call	May. 29
Norway's Circio Sets Terms of NOK52 Million Rights Issue Proposal	May. 29	MT
Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	Apr. 17	MT
Circio to Raise Up to NOK60 Million via Rights Issue	Apr. 17	MT
Circio Terminates Cancer Vaccine License Deal in China	Apr. 17	MT
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus	Apr. 17	CI
Transcript : Circio Holding ASA - Special Call	Apr. 17
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment	Apr. 17	CI
Circio Partner Exercises Option to License Cancer Vaccine in China	Mar. 19	MT
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China	Mar. 19	CI
Atlas Special Opportunities Converts Circio's Convertible Bonds to Shares	Feb. 05	MT
Circio Doses First Patient in Phase 2 Trial of Cancer Vaccine	Feb. 01	MT
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University	Feb. 01	CI
Circio Gets Approval for EUR6 Million Loans Waiver for Tumor Cell Technology Development	Jan. 18	MT
Circio Holding Asa Receives Waiver of Eur 6.2 Million in Loans from Business Finland	Jan. 18	CI
Atlas Special Opportunities Converts NOK1 Million of Circio Convertible Bonds	Jan. 10	MT
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration	Dec. 12	CI
Circio Partner Files Investigational New Drug Application for Cancer Vaccine in China	Dec. 12	MT
Circio to Begin Clinical Trial for Blood Cancer Vaccine After Successful Safety Review	Dec. 07	MT
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital	Dec. 07	CI
Transcript : Circio Holding ASA - Special Call	Nov. 29

Chart Circio Holding ASA

Duration

Period

More charts

Company Profile

Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circioâs second clinical program is an immunotherapy targeting KRAS driver mutations.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.45 NOK

Average target price

12 NOK

Spread / Average Target

+389.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CIRCIO HOLDING ASA	-65.97%	2.45M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs